Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
John Kheir, MD, discusses his journey to find a way to oxygenate blood without the use of lungs. Using microparticles injected with oxygen, Kheir and his team were…
As we age, bones become less dense, increasing the risk of hip and other bone fractures. Testing bone mineral density is one way physicians assess a patient’s fracture…
What if it were possible to combine the technological capabilities of an entire laboratory on one single chip? Scientists all across Europe may be getting close. Scientists at…
NEW YORK (Reuters Health) – A novel VEGFR inhibitor, tivozanib, improves progression-free survival significantly in patients with metastatic renal cell carcinoma but does not improve overall survival, according…
NEW YORK (Reuters Health) – After primary surgery for early-stage endometrial cancer, adjuvant external beam radiation therapy confers no survival benefit overall, according to a Norwegian study. In…
Many of Uganda’s health centers are located in remote areas, where there is not adequate health information and poor delivery systems. Subsequently, these facilities are not able to…
Born with a rare neuromuscular condition called Arthrogryposis Multiplex Congenita, two-year-old Emma Lavelle has severely contracted joints and muscle weakness leaving her without the ability to lift her…
Drug and alcohol addiction is often a chronic or ongoing problem like smoking and depression. Many health systems are looking to treat these conditions by implementing coordinated chronic…
NEW YORK (Reuters Health) – Among several different DNA-based quantitative polymerase chain reaction (qPCR) assays for detecting a critical JAK2 mutation in myeloproliferative neoplasms, one stands out as…
NEW YORK (Reuters Health) – There’s no evidence that starting treatment with the anti-obesity drug orlistat raises the likelihood of developing colorectal cancer, at least in the short…
